Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | HTR3A | P46098 | 9/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6766932 | 0.86 | HTR1A (0.50) | HTR1ADRD2DRD3HTR3AHTR7 | |
| SCHEMBL6770311 | 0.85 | HTR1A (0.49) | HTR1ADRD2DRD3HTR3AHTR7 | |
| SCHEMBL6777478 | 0.85 | HTR1A (0.49) | HTR1ADRD2DRD3HTR3AHTR7 | |
| SCHEMBL6776208 | 0.85 | HTR1A (0.49) | HTR1ADRD2DRD3HTR3AHTR7 | |
| SCHEMBL6770088 | 0.82 | HTR1A (0.46) | HTR1ADRD2DRD3HTR3A | |
| SCHEMBL6776983 | 0.82 | HTR1A (0.45) | HTR1ADRD2DRD3HTR3A | |
| SCHEMBL6766277 | 0.81 | HTR1A (0.45) | HTR1ADRD2DRD3HTR3A | |
| SCHEMBL6777471 | 0.80 | HTR1A (0.57) | HTR1ADRD2DRD3HTR3AHTR7 | |
| SCHEMBL6766799 | 0.80 | HTR1A (0.54) | HTR1ADRD2DRD3HTR3AHTR7 | |
| SCHEMBL7048510 | 0.79 | SIGMAR1 (0.41) | HTR7HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6821967-B2 | AMINES SUCH AS 9-(4-(4-(BENZOTHIAZOL-2-YL)-PIPERAZIN-1-YL)-BUTYL)-9H-FLUORENE-9-CARBOXYLIC ACID (2,2,2-TRIFLUOROETHYL) AMIDE, USED AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ANTAGONISTS, TO PREVENT ATHEROSCLEROSIS OR HYPERLIPEMIA | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-11-23 | — | — | US | disclosed |
| US-20030166637-A1 | Substituted piperazine derivatives, the preparation thereofand their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166637-A1 | Substituted piperazine derivatives, the preparation thereofand their use as medicaments | MTTP, CETP, CPT1A | HTR1A 1523/4885DRD2 3337/4885DRD3 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.